BofA update shows where active managers are putting money
SEATTLE—Trupanion, Inc. (NASDAQ:TRUP) CEO Margaret Tooth recently sold 4,000 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The shares were sold on March 20 at a weighted average price of $37.175, totaling approximately $148,700. The transaction comes as Trupanion’s stock has shown strong momentum, delivering a 50.53% return over the past year. According to InvestingPro analysis, the stock is currently trading below its Fair Value. This transaction was executed as part of a previously established Rule 10b5-1 trading plan, which Tooth adopted in November 2024 for financial diversification purposes.
In addition to the stock sale, Tooth exercised stock options to acquire 4,000 shares at an exercise price of $8.93 per share. This transaction amounted to a total value of $35,720. Following these transactions, Tooth holds 118,784 shares of Trupanion common stock.
The sales and acquisitions were conducted with no discretion over the timing, as per the trading plan. The weighted average sale price of the shares was calculated from multiple transactions, with prices ranging from $36.96 to $37.41 per share.
Trupanion is a Seattle-based company specializing in medical insurance for pets, and its shares are traded on the NASDAQ exchange under the ticker symbol TRUP. The $1.64 billion market cap company has achieved 15.97% revenue growth over the last twelve months, and analysts expect the company to turn profitable this year. Get deeper insights and access to 12 additional ProTips with InvestingPro.
In other recent news, Trupanion, Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $337.3 million, which slightly surpassed analyst forecasts of $335.46 million. However, the company’s earnings per share (EPS) of $0.04 fell short of the projected $0.07, indicating a 42.9% miss. The pet insurance provider also experienced a 19% year-over-year increase in subscription revenue, reaching $227.8 million. Despite some positive financial outcomes, Trupanion’s growth faced challenges, particularly with a slowdown in subscriber growth and retention rates, as noted by analysts from Stifel and Piper Sandler. Stifel revised its price target for Trupanion from $44 to $41, maintaining a Hold rating, while Piper Sandler reduced its target from $57 to $52 but kept an Overweight rating. The company also announced a write-off of $5.3 million in goodwill related to acquisitions in Europe. Trupanion’s guidance for 2025 indicates a cautious outlook, with projected revenue between $1.379 billion and $1.414 billion and subscription revenue growth expected at 14% year-over-year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.